ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid‐β copathology by Koriath, Carolin et al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 277-280Genetics
ApoE4 lowers age at onset in patients with frontotemporal dementia and
tauopathy independent of amyloid-b copathologyCarolin Koriatha, Tammaryn Lashleyb, William Taylora, Ronald Druyeha,
Athanasios Dimitriadisa, Nicola Denningc, Julie Williamsc, Jason D. Warrend, Nick C. Foxd,e,
Jonathan M. Schottd, James B. Rowef,g, John Collingea, Jonathan D. Rohrerd, Simon Meada,*
aUCL Institute of Prion Diseases, London, UK
bQueen Square Brain Bank for Neurological Disorders, Department of Movement Disorders, UCL Institute of Neurology, London, UK
cUK Dementia Research Institute at Cardiff University, Cardiff, UK
dDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
eUK Dementia Research Institute at UCL, London, UK
fDepartment of Clinical Neurosciences, University of Cambridge, UK
gMedical Research Council Cognition and Brain Sciences Unit, Cambridge, UKAbstract Introduction: ApolipoproteinE (ApoE) is themost important genetic risk factor forAlzheimer’s disease*Corresponding a
3448 4046.
E-mail address: s.
https://doi.org/10.1016
2352-8729/ 2019 Th
(http://creativecommo(AD),withApoE4 thought to enhance andaccelerate amyloid-b (Ab) pathology.ApoE4has recently been
described to increase neurodegeneration in a mouse model of frontotemporal dementia (FTD), in vitro,
and in patients, demonstrating that ApoE4modifies tauopathy independently of Ab. This raises the ques-
tionwhetherApoEgenotype alsomodifies the clinical phenotype inpatientswithFTDwith tau pathology.
Methods: We analyzed 704 patients with FTD, including a genetically and neuropathologically
confirmed subset, and 452 healthy elderly controls. We compared ApoE4 genotype frequency and
age at onset in tau1 or TDP431 FTD patients with or without Ab copathology.
Results: The ApoE4 genotype lowered age at onset in patients with FTD and tau pathology, partic-
ularly once accounting for confounding effects of Ab pathology.
Discussion: We conclude that ApoE4 accelerates neurodegeneration in FTD patients with MAPT
mutations or FTLD-tau pathology, independent of Ab.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Apolipoprotein E (ApoE) is the strongest known common
genetic risk factor for Alzheimer’s disease (AD) [1,2].
Relative to the most common allele (ApoE3), ApoE4 is
associatedwith an increased risk of late-onsetADand an earlier
age at onset (AAO); conversely, ApoE2 confers lower risk and
later onset [2,3].Multiple lines of evidence suggest that ApoE4
risk in AD principally relates to enhanced and accelerated
cerebral Ab pathology [4]. More precisely, ApoE4 appears to
accelerate the early seeding of amyloid pathology, most likely
by decreasing Ab clearance and enhancing Ab aggregation
[5]. Shi et al. recently described how ApoE4 increases theuthor. Tel.: 144 (0) 20 3448 4037; Fax: 144 (0) 20
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ns.org/licenses/by/4.0/).burden of cerebral tau pathology, neuroinflammation, and brain
atrophy in a P301S mouse model of frontotemporal dementia
(FTD) and in vitro; they also demonstrated that in patients
with a primary tauopathy, ApoE4was associated with more se-
vere regional neurodegeneration and thatApoE41ADpatients
with amyloid-b (Ab) pathology showed faster disease progres-
sion [6]. New evidence fromShi et al. demonstrates thatApoE4
modifies tauopathy independent of Ab, raising the question
whether ApoE genotype also influences risk or modifies the
clinical phenotype in patientswith primary tauopathies. Several
studies report an association between ApoE and FTD with a
protective effect for ApoE2 and an increased risk conferred
by ApoE4 [729], whereas another shows no association [10].
A recent publication demonstrated a deleterious effect of
ApoE2 in a tau transgenic mouse model [11]. However, inter-
pretations of the associations of ApoE with the clinicaleimer’s Association. This is an open access article under the CC BY license
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variant AD can be misdiagnosed for FTD, and the fact that
the FTD syndrome comprises tau, TDP-43, or other pathol-
ogies. Prompted byShi et al. [6],we therefore analyzed existing
data we held on 704 patients with FTD and 452 healthy elderly
controls using SPSS25 to test the hypothesis that ApoE geno-
type has a modifying effect on clinical phenotype in those
with or expected to have tau pathology defined by a highly
penetrantMAPT gene mutation or by neuropathological exam-
ination.We found that theApoE4 genotype lowered age at clin-
ical onset in patients with dementia and tau pathology, and was
a particularly strong effect once the confounding effects of am-
yloid b pathology were taken into account.
The patients in this FTD cohort were previously tested for
causative genetic mutations [12] and are described in Table 1.
Patients with causative mutations in genes not typically associ-
atedwithFTDwereexcluded fromthepresent analysis. Patients
were analyzed in groups based on genetic and/or neuropatho-
logical data, patients in whom no causative mutation had
been identified and for whom no neuropathological data were
available either were classified as “clinically diagnosed” and
not included in analyses of genetic subgroups. Dementia and
personality change were the predominant symptoms in our se-
ries (54.7% - 33.3% “behavioral type FTD”, 21.4% “FTD”,
1.1% “Dementia”), followed by aphasia (31.8% - 16.9% pro-
gressive nonfluent aphasia, 13.1% semantic dementia, 1.8%
logopenic progressive aphasia) and additional motor or
muscular symptoms (11.5% - 6.0% corticobasal degeneration,Table 1
Characteristics of patients with frontotemporal dementia (FTD) and healthy elder
All FTD Clinical FTD Co
N 704 449 25
AAO (years) 58.1 58.9 5
N Mutation - - 16
N Neuropathology - - 13
N ApoE41 220 139 8
ApoE41 AAO (years) 57.5 59.1 5
ApoE4- AAO (years) 58.3 58.9 5
N Ab1 - - 4
AAO Ab1 - - 6
AAO Ab- - - 5
AAO (N) ApoE41/Ab - - - 51
AAO (N) ApoE4-/Ab - - - 58
AAO (N) ApoE41/Ab1 - - 56
AAO (N) ApoE4-/Ab1 - - 66
NOTE. AAO refers to age at clinical onset, given in years of age; N refers to num
study; these were all patients from the UCL FTD cohort except patients previously
FTD” refers to the 449 patients with a clinical diagnosis of FTD but without a gene
able neuropathological data.
NOTE. “Confirmed FTD” comprises 255 patients with a genetic or neuropatho
C9orf72 expansions, 53 patients with MAPT mutations, 44 patients with GRN m
as well as one case each with a mutation in CHMP2B, TYROBP, and TARDBPmut
confirmed disease: 70 patients with tau pathology and 65 patients with TDP-43 pa
with neuropathologically confirmed tau pathology also had a genetically confirmed
confirmed TDP-43 pathology were found to also carry a deleterious mutation (13 C
genetically and neuropathologically confirmed diseasewere only counted once, exp
causal mutations in theMAPT gene. “NMutation–TDP” refers to causal mutations
cases) genes, which are known to cause TBK-43 pathology. “N Mutation–Confirm
Subcohorts referring to Ab only include cases with available neuropathological d
information on Ab status was not available; for one tau patient, information on A
at testing. ApoE41 includes all carriers of at least one ApoE4 allele, both homo-2.4% progressive supranuclear palsy, 3.7% FTD with motor
neuron disease, 0.3% inclusion body myositis with Paget’s dis-
ease and FTD). As has been shown previously [7], ApoE4 was
more common in clinically diagnosed FTD compared with
healthy elderly controls; 221 patients (31.4%) and 105 controls
(23.2%)were at least heterozygous forApoE4 (chi-squared test,
P5 .003), carrying either one or two ApoE4 alleles. Based on
Shi et al. [6], we hypothesized that ApoE4 would have a modi-
fying effect on AAO in FTD cases with proven or known or ex-
pected tau pathology. While AAO is known to be highly
correlated among family members with a highly penetrant
MAPT gene mutation [13], here, AAO in confirmed FTD pa-
tients who had MAPT gene mutations or FTLD-tau neuropa-
thology was significantly lower in the presence of an ApoE4
allele (tau1 ApoE41 compared with tau1 ApoE42 patients;
53.0 years vs. 56.9 years, t-test, P5 .043, Fig. 1A). In a further
exploratory analysis, we tested whether ApoE4 also affected
non-tau cases in the same way. However, ApoE4 neither had
modifying effect on AAO in FTD patients with FTLD-
TDP43 neuropathology or in FTD patients without an ascer-
tained cause, nor did sex affect AAO in the different groups
(TDP1ApoE41 compared with TDP1ApoE42: 57.6 years
vs. 58.1 years; clinical FTD ApoE41 compared with clinical
FTDApoE42: 58.7 years vs. 58.9 years; ANOVA, all P values
. 0.05; all Fig. 1A).
Wewent on to test whether the modifying effect of ApoE in
FTD-tau might relate to the presence of Ab copathology
without meeting criteria for a formal pathological diagnosisly controls
nfirmed FTD FTD - tau FTD - TDP Controls
5 104 140 456
6.4 55.7 58.1 76.6
6 53 106 -
9 70 65 -
1 32 44 105
4.9 53.0 58.0 75.2
7.4 56.9 58.1 77.1
4 26 18 -
1.0 60.2 62.2 -
7.1 56.9 58.4 -
.4 (12) 49.3 (6) 56.2 (5) -
.1 (71) 58.4 (31) 58.7 (37) -
.1 (23) 54.9 (15) 58.0 (8) -
.3 (21) 67.0 (11) 65.6 (10) -
ber of cases. “All FTD” comprises all 704 patients with FTD included in this
shown to carry mutations not typically associated with FTD [12]. “Clinical
tic diagnosis despite previous testing on a dementia panel [12] and no avail-
logical confirmation of their diagnosis or both. It includes 59 patients with
utations, five cases with VCP mutations, two cases with TBK1 mutations,
ation. “Confirmed FTD” also includes 139 patients with neuropathologically
thology, as well as 4 neuropathologically confirmed FUS cases. 19 patients
deleterious MAPT mutation, whereas 31 patients with neuropathologically
9orf72 expansion, 17 GRNmutations, 1 TBK1mutation). Patients with both
laining disparities of sums in the table. “NMutation–Tau” refers cases due to
in the C9orf72 (59 cases),GRN (44 cases), TARDBP (one case) and TBK1 (2
ed FTD” comprises all genetically confirmed cases as described previously.
ata. For 7 patients with tau pathology and 5 patients with TDP pathology,
AO was not available. AAO is given in years, and in controls refers to age
and heterozygous.
Fig. 1. ApoE41 status is associated with significantly lower age at onset (AAO) in FTD cases withMAPTmutations or FTLD-tau neuropathology, but not in those
with TDP pathology or in those without an ascertained genetic or neuropathological diagnosis (clinical FTD) (A). ApoE4 carrier status is associated with lower
AAO, whereas Ab copathology was associated with later AAO (B). (B) displays the P values for the regression coefficients ApoE4 and Ab. Each dot corresponds
to theAAOof one case, with themean and 95% confidence intervalmarked in red. The number of patients in each subcohort is given in lineN. For (A),AAOwas not
available for 3 tau1ApoE42 patients, 4 TDP1ApoE42 and 6 TDP1ApoE41 cases, as well as 31 clinical FDApoE42 and 9 clinical FTDApoE41 patients; for
Figure 1B, 62 FTD tau1 patients with available ApoE4 status and neuropathological datawere included; AAOwas not available for 1 ApoE4-Ab2 patient, and the
Ab status was unknown for 7 patients. These cases were excluded from the relevant calculations and from the figures.
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mortem cases were neuropathologically staged according to
Thal phases and Braak and Braak stages [14,15]. A number
of cases (n5 44) scored at Thal phases 0, 1, 2, or 3, but none
reached Thal phase 5 or Braak stage 6, needed for a definitive
diagnosis of AD. ApoE4 carrier status increased the
likelihood of Ab pathology, both in cases with tau and
TDP43 pathology (chi-squared test, P5 .001 and chi-squared
test, P 5 .006, respectively): for the tau1 ApoE41 patients
with FTD and available neuropathology data, 15 of 21
(71.4%) had Ab copathology compared with 11/42 (26.2%)
ApoE42 tau1 cases (chi-squared test, P 5 .001); for the
TDP1ApoE41 FTD cases, 8/13 (61.5%) hadAb copathology
compared with 10/47 (21.3%) of ApoE42 TDP1 cases (chi-
squared test, P 5 .013). The prevalence of Ab copathology
was similarwhen tau1 caseswere comparedwith TDP1 cases
(chi-squared test,P5.259) andwas associatedwithApoE4car-
rier status, both in cases with tau pathology (chi-squared test,
P 5 .001) and without tau pathology (chi-squared test,
P 5 .006). Patients who were positive for Ab pathology were
significantly older at onset than patients who were found to
have no Ab pathology at postmortem (60.9 vs. 57.1 years old,
respectively, t-test, P 5 .024). In patients with FTLD-tau,
ApoE genotype and Ab copathology had independent associa-
tions with age at clinical onset (linear regression, n5 62, ApoE
-10.7 years, P5 5.2! 1025; Ab17.6 years, P5 .002). The
effects ofApoE41 carrier status andAbonAAOwere indepen-
dent of each other both in patients with andwithout tau (univar-
iate ANOVA, P5 .550 and P5 .545, respectively).
Our analyses, carried out in a well-characterized cohort of
patients with FTD, provide evidence that ApoE4 genotype ac-celerates neurodegeneration in patients withMAPTmutations
or FTLD-tau pathology independent of Ab—notably AAO in
FTD-tau cases was on average about 3.9 years earlier in those
who carried an ApoE4 allele. Previously, Shi et al. proposed
that ApoE4 genotype acts through a toxic gain of function
mechanism to exacerbate or modify tau pathology, neuroin-
flammation, autophagy, and reactive astrocyte activation;
they provided extensive evidence in a mouse model of FTD
and in neuropathological cases of tauopathies, as well as clin-
ical support in an AD cohort [6]. Our data further strengthens
this hypothesis providing evidence in human that ApoE4mod-
ifies the clinical phenotype of FTLD-tau, independent of Ab
copathology. While ApoE4 status was associated with Ab co-
pathology at postmortem examination in both tau1 and in
TDP1 cases of FTD, its effect on AAO was specific to
tau1 FTD cases (Fig. 1A). Indeed, ApoE4 and Ab copathol-
ogy were associated with opposing effects on AAO in our
data set in tau1 FTD cases (Fig. 1B). The confounding impact
of Ab copathology, along with the heterogeneous nature of
FTD pathology and the specificity of the effect of ApoE4 on
tau pathology may explain why previous studies of ApoE4
in FTD [7–10] did not detect this influence. Despite the
robust statistical finds and the large cohort of patients with
FTD, analysis of pathological and genemutation–defined sub-
groups inevitably leads to relatively restricted numbers and
therefore further replication will be important.Acknowledgment
The study was funded by the Medical Research Council (UK),
the NIHRQueen Square Dementia Biomedical Research Unit,
C. Koriath et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 277-280280the NIHR Biomedical Research Centre at University College
Hospitals NHS Foundation Trust and Alzheimer’s Research
UK (ARUK). The authors are very grateful to patients and vol-
unteers who have donated blood samples, their time, and their
brains to research and have made this study possible. C.K. is
supported by a Leonard Wolfson Foundation PhD fellowship.
T.L. is supported by an Alzheimer’s Research UK senior
fellowship and Queen Square Brain Bank is supported by
Reta Lila Weston Trust for medical research. J.B.R. is funded
by the Wellcome Trust (103838) and the NIHR Cambridge
Biomedical Research Center. J.D.R. is supported by an MRC
Clinician Scientist Fellowship (MR/M008525/1) and has
received funding from the NIHR Rare Disease Translational
Research Collaboration (BRC149/NS/MH). J.D.W. receives
research support from the Alzheimer’s Society (AS-PG-16-
007) NCF acknowledge support from the UK Dementia
Research Institute. Cardiff were funded by the Medical
Research Council (MR/K013041/1), Alzheimer’s Research
UK (ARUK-PG2014-1), EU Joint Program - Neurodegenera-
tive Disease Research (MR/L501517/1), Welsh Government
(SGR544: CADR), Brains for Dementia Research and the
Moondance Foundation.RESEARCH IN CONTEXT
1. Systematic review: We reviewed the literature
searching for “ApoE” and “frontotemporal demen-
tia” or “FTD”, establishing that other than Shi
et al. (Nature, 2017) little information on the effects
of ApoE on primary tauopathies and FTD was avail-
able. Shi et al. established a primary effect of ApoE4
on tau pathology and neurodegeneration, indepen-
dent of amyloid b (Ab) pathology.
2. Interpretation: Our data in patients with FTD
confirm that ApoE4 exacerbates the disease in pa-
tients with or expected to have tau pathology,
lowering the age at clinical onset significantly.
This effect is more pronounced if confounding ef-
fects of Ab copathology are taken in to account.
3. Future directions: Future studies should analyze the
effects of ApoE genotype on FTD, accounting for
differential effects on tau and Ab copathology, to
replicate the effects found here. Further in vitro
studies to elucidate the cellular mechanisms for
this effect will be important.References
[1] Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M,
Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding
to beta-amyloid and increased frequency of type 4 allele in late-onset
familial Alzheimer disease. Proc Natl Acad Sci United States America
1993;90:1977–81.
[2] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,
Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4
allele and the risk of Alzheimer’s disease in late onset families. Sci-
ence 1993;261:921–3.
[3] Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar
amyloid-beta burden in cognitively normal people at 3 levels of ge-
netic risk for Alzheimer’s disease. Proc Natl Acad Sci United States
America 2009;106:6820–5.
[4] Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E
receptors: normal biology and roles in Alzheimer disease. Cold Spring
Harbor Perspect Med 2012;2:a006312.
[5] Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 Ac-
celerates Early Seeding of Amyloid Pathology. Neuron 2017;
96:1024–1032.e3.
[6] Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L,
Luo W, et al. ApoE4 markedly exacerbates tau-mediated neu-
rodegeneration in a mouse model of tauopathy. Nature 2017;
549:523–7.
[7] Mishra A, Ferrari R, Heutink P, Hardy J, Pijnenburg Y,
Posthuma D. Gene-based association studies report genetic links
for clinical subtypes of frontotemporal dementia. Brain 2017;
140:1437–46.
[8] Rostgaard N, Roos P, Budtz-Jørgensen E, Johannsen P, Waldemar G,
Nørremølle A, et al. TMEM106B and ApoE polymorphisms in
CHMP2B-mediated frontotemporal dementia (FTD-3). Neurobiol Ag-
ing 2017;59:221.e221–221.e227.
[9] Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch CM,
et al. Genetic architecture of sporadic frontotemporal dementia and
overlap with Alzheimer’s and Parkinson’s diseases. J Neurol Neuro-
surg Psychiatry 2017;88:152–64.
[10] Jairani PS, Aswathy PM, Gopala S, Verghese J, Mathuranath PS. Inter-
action with the MAPT H1H1 Genotype Increases Dementia Risk in
APOE epsilon4 Carriers in a Population of Southern India. Demen
Geriatr Cogn Disord 2016;42:255–64.
[11] Zhao N, Liu CC, Van Ingelgom AJ, Linares C, Kurti A, Knight JA,
et al. APOE ε2 is associated with increased tau pathology in primary
tauopathy. Nat Commun 2018;9:4388.
[12] Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, et al.
Predictors for a dementia gene mutation based on gene-panel next-
generation sequencing of a large dementia referral series. Mol Psychi-
atry 2018; https://doi.org/10.1038/s41380-018-0224-0 [Epub ahead of
print].
[13] Dick KM, Boeve BF, Borroni B, Boxer A, Brice A, Butler CR, et al.
Symptom onset in frontotemporal dementia. Alzheimer’s Demen
2017;13:P1337.
[14] Braak H, Braak E. Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991;82:239–59.
[15] Thal DR, R€ub U, Orantes M, Braak H. Phases of A beta-deposition in
the human brain and its relevance for the development of AD.
Neurology 2002;58:1791–800.
